Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 13/20 | 0.73 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.63 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.62 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.57 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11741199 | 0.90 | SIRT1 (0.62) | SIRT1BRD3MAPKAPK2SIRT2SIRT3 | |
| SCHEMBL31328289 | 0.88 | SIRT1 (0.75) | SIRT1BRD3MAPKAPK2SIRT2SIRT3 | |
| SCHEMBL1873883 | 0.85 | SIRT1 (0.79) | SIRT1MAPKAPK2SIRT2SIRT3RECQL | |
| SCHEMBL1674922 | 0.84 | SIRT1 (0.79) | SIRT1MAPKAPK2SIRT2SIRT3LMNA | |
| SCHEMBL1872225 | 0.84 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQLLMNA | |
| SCHEMBL1870436 | 0.84 | SIRT1 (0.73) | SIRT1SIRT2SIRT3RECQLLMNA | |
| SCHEMBL16266024 | 0.82 | MAPT (0.77) | SIRT1BRD3SIRT2SIRT3RECQL | |
| SCHEMBL31328292 | 0.82 | MAPT (0.77) | SIRT1BRD3SIRT2SIRT3RECQL | |
| SCHEMBL9019672 | 0.81 | BRD3 (0.60) | BRD3MAPKAPK2 | |
| SCHEMBL11736040 | 0.81 | SIRT1 (1.00) | SIRT1MAPKAPK2SIRT2SIRT3RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113903-A1 | SirT INHIBITORS THAT BIND TO NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20140163029-A1 | SirT INHIBITORS THAT BIND TO NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20110104177-A1 | HISTONE DEACETYLASE INHIBITORS, COMBINATION THERAPIES AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-05-05 | — | — | US | disclosed |
| US-20100210692-A1 | METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-19 | — | — | US | disclosed |
| US-20090306168-A1 | SirT Inhibitors That Bind to NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090022694-A1 | SIRT1 INHIBITION | ELIXIR PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20080214800-A1 | Deacetylase which uses NAD as a cofactor; treating sirtuin related disorders | ELIXIR PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20050256181-A1 | Treating a viral disorder | ELIXIR PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050209300-A1 | Methods of treating a disorder | IPSOL AG (LI) | 2005-09-22 | — | — | US | disclosed |
| US-4057640-A | ANTIINFLAMMATORY | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-11-08 | — | — | US | disclosed |
| US-3956295-A | ANTIINFLAMMATORY | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113903-A1 | SirT INHIBITORS THAT BIND TO NAD | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885BRD3 488/4885MAPKAPK2 1946/4885 |
| US-20080214800-A1 | Deacetylase which uses NAD as a cofactor; treating sirtuin related disorders | SIRT3, SIRT1, SIRT2 | SIRT1 2/4885BRD3 346/4885MAPKAPK2 3471/4885 |
| US-20100210692-A1 | METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS | SIRT1, SIRT2, SIRT3 | SIRT1 1/4885BRD3 82/4885MAPKAPK2 1096/4885 |
| US-20090022694-A1 | SIRT1 INHIBITION | SIRT1, SIRT2, SIRT3 | SIRT1 1/4885BRD3 184/4885MAPKAPK2 742/4885 |
| US-20110104177-A1 | HISTONE DEACETYLASE INHIBITORS, COMBINATION THERAPIES AND METHODS OF USE | HDAC1, HDAC5, HDAC4 | SIRT1 12/4885BRD3 32/4885MAPKAPK2 1276/4885 |
| US-20140163029-A1 | SirT INHIBITORS THAT BIND TO NAD | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885BRD3 488/4885MAPKAPK2 1946/4885 |
| US-20050209300-A1 | Methods of treating a disorder | CPT1B, CYP27A1, CLN6 | SIRT1 2717/4885BRD3 3230/4885MAPKAPK2 3833/4885 |
| US-20090306168-A1 | SirT Inhibitors That Bind to NAD | SIRT1, SIRT3, SIRT2 | SIRT1 1/4885BRD3 488/4885MAPKAPK2 1946/4885 |
| US-20050256181-A1 | Treating a viral disorder | HAVCR2, EIF2AK2, RPL35 | SIRT1 1460/4885BRD3 1610/4885MAPKAPK2 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.